Efficacy of combination therapy of Methotrexate and Vitamin A in low risk gestational trophoblastic neoplasia treatment

Authors

Abstract:

Introduction: Methotrexate as a single agent chemotherapy in most women with low risk gestational trophoblastic neoplasia (GTN) has been associated with high treatment rate. Combination of methotrexate with Vitamin A due to reduced number of chemotherapy regime courses is one of the treatment options for patients with low-risk GTN. Therefore, this study was performed with aim to determine the efficacy of combination therapy of Methotrexate with Vitamin A in low risk GTN treatment. Methods: This randomized clinical trial was performed on 49 patients with low risk gestational trophoblastic neoplasia. The treatment group (Group A= 19 cases) weekly received Methotrexate 50 mg/m2, and Vitamin A 200000 IU, intra-muscular, and the control group (Group B= 30 cases) only received Methotrexate 50 mg/m2 weekly . All patients were followed up for 8 weeks. Then, treatment outcomes were compared between two groups, and response to therapy was assessed in two groups by evaluation of HCG serum level. P Results: Mean of B-HCG serum level after 4 weeks in Group A and Group B was 68.5 mIu/ml and 360mIu/ml , respectively (P=0.018), and after 8 weeks was 1 mIu/ml and 12mIu/ml, respectively (P=0.074). Conclusion: Combination therapy of Methotrexate and Vitamin A in low risk GTN is associated with shorter duration of chemotherapy.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Comparison of Two Therapeutic Regimens: Methotrexate-Folinic Acid (8 days) and Weekly Methotrexate in Patients with Low risk Gestational Trophoblastic neoplasia

Background: Methotrexate is used in the treatment of Low-risk Gestational Trophoblastic Neoplasia. The purpose of this study was to compare the therapeutic responses and side effects of two therapeutic methods which were prescribed for patients suffering from Low-risk Gestational Trophoblastic Neoplasia. One method was the daily use of Methotrexate-Folic Acid (for 8 da...

full text

Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimen in gestational trophoblastic neoplasia

Background: Gestational trophoblastic neoplasia (GTN) originates from placental trophoblast and is a highly chemosensitive and curable gynecologic malignancy. The present study was conducted to evaluate the effectiveness and safety of EMA/EP (etoposide, methotrexate, actinomycin-D, etoposide, and cisplatin) regimen in the treatment of high-risk GTN as well as patients’ outcome.  &nb...

full text

Comparison of the efficacy of methotrexate and actinomycin D in the treatment of patients with stage I low risk gestational tro-phoblastic neoplasia (GTN)

  Background : Gestational trophoblastic neoplasia (GTN) refers to malignant lesions that arise from abnormal proliferation of placental trophoblast. Even in its metastatic forms GTN is curable with a cure rate of 90-100 %. Currently, methotrexate with or without folic acid, andactinomycin D is recommended for low risk GTN. The aim of this study is to compare the efficacy of methotrexate and ac...

full text

Single-Agent Therapy for Low Risk Gestational Trophoblastic Neoplasia (LRGTN): A Preliminary Report on a Randomized Clinical Trial to Compare Pulse-Methotrexate versus Pulse-Dactinomycin

The efficacy of single-agent chemotherapy for patients with low risk gestational trophoblastic neoplasia (LRGTN) with methotrexate or dactinomycin is well established, but efforts continue to reduce the toxicity, the patients time and cost of treatment. In a randomized clinical trial, we evaluated and compared the efficacy, toxicity and cost effectiveness of pulse-methotrexate versus pulse-dact...

full text

The Evolution of Methotrexate as a Treatment for Ectopic Pregnancy and Gestational Trophoblastic Neoplasia: A Review

Methotrexate was developed in 1949 as a synthetic folic acid analogue to compete with folic acid and thus interfere with cell replication. While initially developed as a potential treatment for acute lymphoblastic leukaemia, a serendipitous observation led to methotrexate's use to effect the dramatic cure of a case of advanced choriocarcinoma. This prompted the exploration for the potential of ...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 17  issue Special Issue

pages  38- 42

publication date 2018-03-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023